期刊文献+

格列齐特缓释片的人体药物动力学及相对生物利用度 被引量:3

Pharmacokinetics and relative bioavailability of gliclazide modified release tablets in healthy volenteers
下载PDF
导出
摘要 目的研究2种格列齐特缓释片的人体药物动力学及相对生物利用度。方法40例健康受试者采用随机交叉给药方案,单次或多次口服60 mg供试或参比格列齐特缓释片后,采用HPLC测定人体血浆中格列齐特的浓度,计算其药物动力学参数和相对生物利用度,评价两制剂的生物等效性。结果单次口服格列齐特缓释片供试制剂和参比制剂主要药物动力学参数Cmax分别为(2.92±1.29)和(2.73±1.39)μg.mL^-1,tmax分别为(6.9±2.1)和(6.3±2.0)h,t1/2分别为(14.63±3.06)和(15.89±3.46)h,AUC0-60分别为(53.82±17.58)和(57.11±22.67)μg.h.mL^-1。多次口服格列齐特缓释片达稳态后供试和参比制剂主要药物动力学参数Cssmax分别为(3.33±1.07)、(3.11±1.22)μg.mL^-1,Tsmsax分别为(54.3±1.9)和(54.5±2.5)h,Cmin分别为(0.20±0.19)和(0.19±0.20)μg.mL^-1,Cav分别为(1.11±0.64)和(1.10±0.63)μg.mL^-1,AUCSS分别为(119.92±68.94)和(119.10±68.20)μg.h.mL^-1。结论建立的格列齐特分析方法简单、快速、准确。2种制剂具有生物等效性。 Objective To determine the pharmacokinetics and relative bioavailability of gliclazide modified release tablets in Chinese healthy volunteers. Methods A single oral dose of 60 mg gliclazide modified release tablets of reference or test drugs was given to each volunteer according to an open randomized crossover study. The concentrations in the plasma were determined by reverse-phase pair HPLC. Pharmacokinetics and bioequivalence of the two formulations were also studied. Results The main pharmacokinetic parameters after a single oral doses of gliclazide modified release tablets were as follows: Cmax was (2. 92±1.29) μg · mL^- 1 and (2.73±1.39) μg · mL^- 1 respectively; tmax was (6. 9± 2. 1)h and (6.3±2.0) h respectively; t1/2 was (14.63±3.06) h and (15.89±3.46) h respectively; AUC0-60 was (53.82±17.58) μg · h · mL^- 1 and (57.11±22. 67) μg · h · mL^- 1 respectively. The steady state pharmacokinetic parameters after the multiple doses of gliclazide modified release tablets were as follows. Cmax was (3. 33 ± 1. 07) μg · mL^- 1and (3.11±1.22)μg · mL^- 1respectively; tmax was (54. 3±1.9) h and (54.5±2. 5) h, respectively; Cmax was (0. 20±0. 19) h and (0. 19±0.20) μg · mL^- 1respectively; Cmax was (1.1±10. 64) μg · mL^- 1 and (1.10±0.63) μg · mL^- 1 ; AUCss was (119.92±68.94)μg · h · mL^- 1 and (119.10+68.20)μg · h · mL^- 1, respectively. Conclusion This method is sensitive, accurate and simple. The two preparations are bioequivatent.
出处 《中南药学》 CAS 2007年第3期236-238,共3页 Central South Pharmacy
关键词 格列齐特缓释片 高效液相色谱 药物动力学 生物等效性 gliclazide modified release tablets HPLC pharmacokinetics bioequivalence
  • 相关文献

参考文献7

二级参考文献17

共引文献22

同被引文献17

  • 1谭建国,向大雄,张毕奎.格列齐特生物黏附缓释片的研制及体外评价[J].中南药学,2005,3(2):84-86. 被引量:9
  • 2邱相君,黄成坷,钱昕,胡国新,代宗顺.格列齐特的人体生物等效性研究[J].医药导报,2006,25(9):874-876. 被引量:5
  • 3张毕奎,苏芬丽,向大雄,朱运贵,谭建国,许飞,李焕德.格列齐特生物黏附缓释片的研制及其体内体外评价[J].中国药学杂志,2007,42(12):910-913. 被引量:14
  • 4张象麟.药物临床信息参考[M].重庆:重庆出版社,2008:674-675.
  • 5Rouini MR,Mohajer A,Tahami MH.A simple and sensitive HPLC method for determination of gliclazide in human serum.J Chromatogr B Analyt Technol Biomed Life Sci,2003,785:383-386.
  • 6Kim H,Yun M,Kwon KI.Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers[J].Arch Pharm Res,2003,26(7):564-572.
  • 7Wu CZ,Pei D,Hsieh AT,et al.Comparison of insulin sensitivity,glucose sensitivity,and first phase insulin secretion in patients treated with repaglinide or gliclazide[J].Arch Pharm Res,2010,33(3):411-416.
  • 8Rambiritch V,Naidoo P.Gliclazide modified release[J].Drugs,2005,65(10):1449-1450.
  • 9Dourakis SP,Tzemanakis E,Sinani C,et al.Gliclazide-induced acute hepatitis[J].Eur J Gastroenterol Hepatol,2000,12(1):119-121.
  • 10Wang CY,Zhang W,Xiang BR,et al.Liquid chromatography-mass spectrometry method for the determination of gliclazide in human plasma and application to a pharmacokinetic study of gliclazide sustained release tablets[J].Arzneimittelforschung,2008,58(12):658-666.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部